OncoMatch/Clinical Trials/NCT04771130
A Study of BGB-11417 in Participants With Myeloid Malignancies
Is NCT04771130 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for acute myeloid leukemia.
Treatment: BGB-11417 · Azacitidine · Posaconazole · BGB-11417 · BGB-11417 — The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Biomarker criteria
Excluded: ABL1 fusion
Excluded: BCR fusion
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: B-cell lymphoma-2 inhibitor
Prior therapy with a B-cell lymphoma-2 inhibitor
Lab requirements
Kidney function
creatinine clearance ≥ 50 ml/min (or between 30 and 49 ml/min in unfit aml cohort)
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope National Medical Center · Duarte, California
- Tampa General Hospital · Tampa, Florida
- Upmc Hillman Cancer Center(Univ of Pittsburgh) · Pittsburgh, Pennsylvania
- Md Anderson Cancer Center · Houston, Texas
- Medical College of Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04771130 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior B-cell lymphoma-2 inhibitor disqualifies patients from enrollment.
Are patients with ABL1 alterations eligible?
No. ABL1 fusion is an exclusion criterion.
Are patients with BCR alterations eligible?
No. BCR fusion is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify